Open access
Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
T. Tsujino
K. Tamura
R. Taoka
M. Miyake
K. Kobayashi
Y. Sasaki
K. Ogawa
S. Tatarano
S. Katayama
M. Kato
Y. Abe
Y. Oda
K. Wada
Junya Furukawa
Motoo Araki
H. Enokida
Koji Shiraishi
K. Inoue
T. Inamoto
Haruhito Azuma
Medicine
Abstract
Enfortumab vedotin (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma. Further characterization of clinical heterogeneity and toxicity may complement existing Japanese real‐world data.